Brief: Chemomab Therapeutics Names David M. Weiner, MD As Interim Chief Medical Officer
03/12/2021 13:25
Dec 3 (Reuters) - Chemomab Therapeutics Ltd CMMB.O :
* CHEMOMAB THERAPEUTICS NAMES DAVID M. WEINER, MD AS INTERIM
CHIEF
MEDICAL OFFICER
Source text for Eikon: ID:nPn5X46fla
Further company coverage: CMMB.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Chemomab Therapeutics
See all newsBrief: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results And Provides Corporate Update
Chemomab Therapeutics Ltd expected to post a loss of 15 cents a share - Earnings Preview
Israel's Chemomab Q4 net loss narrows on lower R&D spend
Brief: Chemomab Therapeutics Announces Nebokitug Phase 2 Spring Trial Results
Brief: Chemomab Therapeutics Announces Third Quarter 2025 Financial Results And Provides Corporate Update